Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928642 · ClinicalTrials.gov registry record · Phase 2
Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer
A Phase 2 study, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00928642: Completed Phase 2 study, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
NCT00928642 is a Phase 2 study that has completed, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00928642, a Phase 2 study, has completed, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy drug used. Participation in the treatment portion of the study will continue as long as the patient's tumors shrink or remain stable and as long as the patient is able to tolerate the study drug. The follow-up portion of the study will last for 5 years.
Primary Outcome
Progression free survival at six months was assessed for all research subjects. Progression defined by SWOG criteria: Invest New Drugs. 1992 Nov;10(4):239-53. Progression is defined as \> 50% increase in the sume of measured cross sectional area of areasa of measurable disease, measured from the lowest measured amount of disease. Progression is also defined as new areas of measurabe disease.
Interventions
- DRUG imatinib mesylate by mouth
- DRUG Gemcitabine Intravenous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
What the finished NCT00928642 record still lists
NCT00928642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which imatinib mesylate by mouth is the first listed.
NCT00928642 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00928642 about?
NCT00928642 is a clinical study titled "Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer". This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy dru...
What is the current status of trial NCT00928642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2009-06. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00928642?
The interventions under investigation include: imatinib mesylate by mouth (DRUG), Gemcitabine Intravenous (DRUG).
Who is sponsoring clinical trial NCT00928642?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00928642's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia